Education
About Us
Working with TipRanks
Follow Us
Sartorius AG (IT:1SRT)
:1SRT
Earnings Data
Report Date
Apr 16, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
1.19Last Year’s EPS
1.01Same Quarter Last Year
Moderate Buy
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Apr 16, 2025
|% Change Since: 18.58%
|Next Earnings Date:Jul 22, 2025
Earnings Call Sentiment|Positive
The earnings call presented a strong start to 2025 with significant growth in consumables and margin expansion. However, challenges in equipment sales, particularly in the Lab Products & Services division, and potential impacts from tariffs were noted. The overall performance was positive, with strategic acquisitions and strong cash flow contributing to an optimistic outlook.Company Guidance
In the first quarter of 2025, Sartorius AG and Sartorius Stedim Biotech reported a 6.5% sales revenue growth in constant currencies and a robust book-to-bill ratio above one. The Bioprocess Solutions division led the growth with a 10% increase in sales revenue, driven by strong double-digit growth in consumables, although equipment sales remained muted. The Lab Products & Services division faced challenges with a 5.5% decline in constant currencies due to soft equipment sales. The company announced its guidance for 2025, expecting approximately 6% sales revenue growth for the group, with an underlying EBITDA margin of 29% to 30%. Sartorius also highlighted a strategic acquisition of MatTek, enhancing its portfolio in advanced cell models, and discussed measures to address tariffs, aiming to maintain competitive positioning without impacting EBITDA margins.Impressive Start to 2025
Sartorius reported a strong start to the fiscal year with a 6.5% sales revenue growth in constant currencies and a book-to-bill ratio above one for both divisions.
Double-Digit Growth in Consumables
The Bioprocess Solutions division saw a 10% revenue increase, driven by strong demand for consumables.
Significant Margin Expansion
Underlying EBITDA margin increased by 120 basis points to 29.8% due to scale effects, improved product mix, and efficiency programs.
Strong Cash Flow and Deleveraging
Operating cash flow tripled compared to the previous year, contributing to a reduction in the leverage ratio as planned.
Robust Regional Growth
The Americas region showed the strongest growth, with double-digit increases in the Bioprocess Solutions division.
MatTek Acquisition
Sartorius acquired MatTek, a leading provider of human cell-based microtissues and 3D models, for $80 million to enhance its advanced cell models portfolio.
---
IT:1SRT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
IT:1SRT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Apr 16, 2025 | €160.40 | €173.60 | +8.23% |
| Jan 28, 2025 | €197.77 | €222.07 | +12.29% |
| Oct 17, 2024 | €180.04 | €206.13 | +14.49% |
| Jul 18, 2024 | €195.98 | €195.58 | -0.20% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Sartorius AG (IT:1SRT) report earnings?
Sartorius AG (IT:1SRT) is schdueled to report earning on Apr 16, 2025, TBA Not Confirmed.
What is Sartorius AG (IT:1SRT) earnings time?
Sartorius AG (IT:1SRT) earnings time is at Apr 16, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Sartorius AG stock?
The P/E ratio of Sartorius is N/A.
What is IT:1SRT EPS forecast?
IT:1SRT EPS forecast for the fiscal quarter 2025 (Q1) is 1.19.
---